The antiviral BDGR-49 provides protection from lethal, neurotropic Venezuelan equine encephalitis virus intranasal infection in mice
Journal of Virology · 2025
DOI: 10.1128/jvi.01679-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Evan P Williams und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee, …. Hauptthemen laut MEDLINE: Encephalitis Virus, Venezuelan Equine, Encephalomyelitis, Venezuelan Equine, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Venezuelan, western, and eastern equine encephalitis virus (VEEV, WEEV, and EEEV) cause a febrile illness that may result in fatal neurological disease in humans and equines. Human infections are typically from mosquito bites, although cases from respiratory exposure in laboratory accidents have been documented. In addition to natural mosquito-borne infection, the potential biothreat inherent in the ability to disseminate these viruses via the respiratory route has driven the development of antiviral drugs for this route of exposure. To address this gap, we tested the prophylactic administration of a novel brain-penetrant, antiviral, BDGR-49, against a lethal intranasal challenge of VEEV, WEEV, or EEEV in BALB/c mouse model. BDGR-49 conferred 100% protection with 6 mg kg −1 twice per day for 6 days for VEEV, but not EEEV or WEEV. By 8 days post-infection (dpi), infectious virus, viral RNA, and viral antigen in the brain of BDGR-49-treated mice were significantly reduced. Brains of VEEV TrD-infected, BDGR-49-treated mice showed a significant reduction in the expression of genes associated with inflammation ( IFNB1 , TNF , IL6 , and CCL5 ) and cell death ( CASP4 , GSDMD , PYCARD , and ZBP1 ). At dpi 14, histopathology showed that neuronal lesions and inflammatory cell infiltrates were essentially absent, and viral antigen was not detected in the brains of VEEV TrD-infected, BDGR-49-treated mice. In summary, although BDGR-49 treatment showed significant promise for the treatment of mice exposed intranasally to VEEV, the more rapid and efficient entry of EEEV and WEEV by this route into the central nervous system will require additional optimization of the dosing regimen. IMPORTANCE Prophylactic and therapeutic treatment of viruses that cause encephalitis requires fast-acting drugs that rapidly penetrate the blood-brain barrier. Currently, clinicians have only a limited set of antivirals for the treatment of neurotropic infections such as herpesviruses or HIV-1, and none for alphaviruses, and treatment outcomes remain poor. New medical countermeasures will address the gap in treatment of viral encephalitis such as those caused by the neurotropic alphaviruses and others.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Animal Resources Center and Veterinary Pathology Core, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Regional Biocontainment Laboratory, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Center for Advanced Biotechnology and Medicine, Rutgers The State University of New Jersey, Piscataway, New Jersey, USA.
ORCID-Profile: Evan P Williams, Jennifer E Golden, Bernd Meibohm, Colleen B Jonsson
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Williams, E. P., Xue, Y., Vogel, P., Yang, D., Ponce-Flores, A., Li, X., Ogorek, T. J., Saini, M., Iulek, J., Ruiz, F. X., Arnold, E., Golden, J. E., Meibohm, B., & Jonsson, C. B. (2025). The antiviral BDGR-49 provides protection from lethal, neurotropic Venezuelan equine encephalitis virus intranasal infection in mice. Journal of Virology. https://doi.org/10.1128/jvi.01679-24
Vancouver
Williams EP, Xue Y, Vogel P, Yang D, Ponce-Flores A, Li X, et al. The antiviral BDGR-49 provides protection from lethal, neurotropic Venezuelan equine encephalitis virus intranasal infection in mice. Journal of Virology. 2025. doi:10.1128/jvi.01679-24
BibTeX
@article{Williams2025,
author = {Williams, Evan P and Xue, Yi and Vogel, Peter and Yang, Dong and Ponce-Flores, Alejandro and Li, Xiaoyu and Ogorek, Tyler J and Saini, Manisha and Iulek, Jorge and Ruiz, Francesc Xavier and Arnold, Eddy and Golden, Jennifer E and Meibohm, Bernd and Jonsson, Colleen B},
title = {The antiviral BDGR-49 provides protection from lethal, neurotropic Venezuelan equine encephalitis virus intranasal infection in mice},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.01679-24}
}
EUVIMED